Overview
The Ottawa Heart Failure Risk Scale (OHFRS) is a weighted clinical decision support tool designed for adults presenting to the emergency department with acute heart failure. Rather than establishing a diagnosis, it estimates the probability of serious adverse events within approximately 14 days after the index visit. In prospective validation work, the scale has been used to stratify patients whose disposition (for example, admission versus discharge with close follow-up) could reasonably be influenced by an objective estimate of short-term risk.
The instrument integrates information that is usually available during an emergency department evaluation: relevant medical history, arrival vital signs, a structured reassessment after initial therapy (including a brief walk test when feasible), the electrocardiogram, and selected laboratory studies. An optional natriuretic peptide threshold can be incorporated when quantitative NT-proBNP is measured. The result is a single additive score with a defined maximum, which maps onto broad risk strata that clinicians can interpret alongside bedside judgment, comorbidity, trajectory of illness, and social context.
Why a dedicated heart failure risk scale matters
Acute heart failure is common, heterogeneous, and expensive to manage. Many patients require hospital-level monitoring, diuresis, afterload reduction, treatment of precipitants, and careful titration of chronic guideline-directed medical therapy. Others stabilize quickly with emergency department therapy and can be managed safely as outpatients if follow-up is reliable and red flags are understood. The difficulty is that clinical gestalt alone is imperfect for predicting which patients will experience deterioration, need escalated care, or return with relapse in the very near term.
The OHFRS was developed to make short-term risk more explicit by encoding factors repeatedly associated with worse outcomes in this population. It does not replace specialist consultation when indicated, nor does it determine the appropriateness of every intervention. Instead, it provides a transparent checklist that encourages thoroughness (for example, ensuring ischemia, renal stress, and myocardial injury are considered) and communicates risk in a way that teams, patients, and trainees can understand.
Intended population and when to apply the scale
The OHFRS is intended for emergency department patients with acute decompensated heart failure in whom the clinician is weighing disposition and intensity of monitoring. Typical presentations include dyspnea, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, elevated jugular venous pressure, pulmonary crackles, and corroborating findings such as cardiomegaly or pulmonary edema on imaging, often supported by elevated natriuretic peptides when available.
The scale is least helpful when immediate pathways supersede risk scoring. Examples include cardiogenic shock, severe hypoxemic respiratory failure requiring emergent escalation, sustained malignant arrhythmia, acute coronary syndromes that mandate invasive management independent of disposition scoring, and other conditions where the correct action is determined by resuscitation priorities rather than a 14-day risk estimate. In addition, the scale does not capture every determinant of safe discharge, including frailty, cognitive impairment, substance use, homelessness, medication access, caregiver availability, and ability to recognize worsening symptoms.
Structure of the score
The OHFRS is a weighted additive model. Each criterion is binary for clinical use: either it is met or it is not. Some criteria depend on numeric thresholds (heart rate, oxygen saturation, urea, bicarbonate, NT-proBNP), while others depend on historical events, electrocardiographic interpretation, or troponin elevation interpreted in the context of myocardial infarction definitions. The points assigned to each item reflect the relative contribution of that factor in the derivation and validation analyses. The maximum total score is 15 points when all criteria are present.
Historical factors
Prior stroke or transient ischemic attack
A history of stroke or TIA contributes a modest increment to the score. Cerebrovascular disease frequently coexists with advanced cardiovascular disease and may mark patients with reduced physiologic reserve, atrial arrhythmia burden, adherence challenges, or multimorbidity that complicates heart failure management. While this item is not a direct measure of current hemodynamics, it helps identify a subgroup with higher baseline vulnerability to complications and readmission.
Prior intubation for respiratory distress
A history of endotracheal intubation for respiratory distress receives a larger weight than many other historical variables. Prior invasive ventilatory support suggests that the patient has previously crossed a threshold of respiratory failure severe enough to require airway and ventilatory intervention. In acute heart failure, such a history may signal recurrent pulmonary edema, marginal respiratory mechanics, sleep-disordered breathing, or tenuous cardiopulmonary reserve. Clinicians often interpret this finding as a prompt for cautious disposition and lower threshold for monitored care during recurrent exacerbations.
Arrival vital signs
Tachycardia on emergency department arrival
Heart rate at or above 110 beats per minute on arrival is assigned substantial weight. Persistent tachycardia may reflect sympathetic activation, pain, arrhythmia, fever, anemia, hypovolemia, pulmonary embolism, or inadequate control of underlying heart rate in atrial fibrillation, in addition to the hemodynamic stress of decompensated heart failure. In heart failure exacerbations, an elevated heart rate can also indicate a patient who is not yet compensated despite initial therapy, or who may deteriorate if afterload reduction and diuresis do not proceed smoothly.
Hypoxemia on arrival
An oxygen saturation below 90 percent on arrival contributes additional risk points. Hypoxemia may be multifactorial, including alveolar flooding from cardiogenic pulmonary edema, ventilation-perfusion mismatch, concomitant pulmonary disease, mucus plugging, or incorrect measurement technique. Regardless of mechanism, low saturation at presentation often correlates with greater respiratory work and a higher likelihood of needing supplemental oxygen strategies, noninvasive positive pressure support, or escalation if therapy fails.
Practical interpretation should account for whether the value was obtained on room air versus usual home oxygen, and whether the patient was speaking, ambulatory, or in distress during measurement. The scale’s intent is to capture meaningful hypoxemia as assessed in routine emergency department practice; local documentation standards may clarify how arrival saturations are recorded.
Reassessment after emergency department treatment: the walk test component
A distinctive element of the OHFRS is functional reassessment after initial emergency department management. After therapy aimed at stabilizing the patient (for example, diuresis, nitrates when appropriate, and optimization of airway and oxygenation), clinicians perform a three-minute walk test and observe the heart rate response.
If the heart rate during this test reaches 110 beats per minute or higher, the walk test criterion is satisfied. If the patient is too ill to perform the test, the derivation treats that situation as meeting the criterion as well, because inability to participate often reflects residual instability, profound dyspnea, hypoxemia, orthostatic intolerance, or other safety concerns. This design acknowledges that the most fragile patients may not generate walk-test data yet remain high risk.
Operational consistency matters: teams should agree on a standard approach to test conditions (flat corridor versus treadmill substitutes, use of usual oxygen delivery, assistance for fall risk) so that the binary item reflects comparable physiologic stress across patients.
Electrocardiogram
New ischemic changes
The presence of new ischemic changes on the ECG adds meaningful points. Acute heart failure frequently overlaps with acute coronary syndrome, demand ischemia, or arrhythmia-related perfusion abnormalities. Electrocardiographic evidence of ischemia should trigger parallel pathways: serial troponins when indicated, consideration of cardiology involvement, risk stratification for coronary disease, and vigilance for rhythm disturbances. Even when chest pain is not the dominant complaint, ischemia can be silent or overshadowed by dyspnea, particularly in older adults and patients with diabetes.
Laboratory markers
Elevated urea (azotemia)
Serum urea at or above 12 mmol/L (often discussed alongside blood urea nitrogen in alternate units) contributes a point. Azotemia may reflect prerenal physiology from poor forward flow or diuretic-related underfilling, intrinsic renal disease, or nephrotoxic exposures. In acute heart failure, renal function is both a marker of end-organ perfusion and a major determinant of medication choices, diuretic responsiveness, and prognosis. Elevated urea should prompt attention to volume status, blood pressure, concomitant nephrotoxins, and the need for laboratory monitoring during therapy.
Elevated serum bicarbonate (reported as CO2 on many chemistry panels)
Serum bicarbonate at or above 35 mmol/L receives a higher weight than urea alone. Marked elevations may accompany chronic respiratory acidosis, metabolic alkalosis from diuretics or vomiting, or compensatory responses in mixed acid-base disturbances. In the emergency department context, unexpected bicarbonate elevation should prompt correlation with blood gas interpretation when available, review of diuretic and electrolyte status, and consideration of comorbid pulmonary disease. The item’s value lies in prompting a second look at acid-base homeostasis, which can be destabilized quickly during aggressive diuresis or in patients with marginal respiratory reserve.
Troponin elevation to myocardial infarction levels
Troponin elevation consistent with myocardial infarction thresholds adds substantial points. Type 1 myocardial infarction due to plaque rupture and Type 2 injury from supply-demand mismatch both can present with heart failure symptoms. Emergency providers must interpret troponin in the context of symptoms, timing, ECG changes, renal function, and baseline chronic elevations. When troponin meets infarction criteria, disposition and monitoring decisions often shift toward pathways that address coronary risk, antithrombotic strategy, and inpatient observation even if dyspnea improves with diuresis.
NT-proBNP threshold
When quantitative NT-proBNP is available, values at or above 5000 ng/L (equivalently pg/mL in common reporting) add a point. Very high natriuretic peptides generally reflect severe myocardial stretch and neurohormonal activation. While natriuretic peptides are not specific to a single diagnosis and can be influenced by age, renal function, obesity, and rhythm, extreme elevations often align with more pronounced congestion and higher short-term event rates. If NT-proBNP is not measured, this component is simply omitted from the summed score in routine clinical application, which is why calculator implementations treat it as an optional criterion tied to availability of the result.
Interpreting the total score and risk strata
After summing applicable items, the OHFRS places patients into broad categories that align with progressively higher observed rates of serious adverse outcomes in validation cohorts. A score of zero identifies the lowest stratum, but it is not synonymous with “no risk.” Even low strata retain a nonzero event rate in prospective data, which is why shared decision-making, clear return precautions, and timely outpatient follow-up remain essential when discharge is considered.
Scores in the low single digits correspond to intermediate strata where event frequencies rise compared with zero. Mid-range scores are associated with materially higher risk, often prompting stronger consideration of monitored settings, prolonged emergency department observation, or hospital admission depending on system resources and patient-specific factors. High totals identify patients in whom short-term complications are common enough that aggressive monitoring, specialist involvement, and detailed transition planning are usually appropriate.
Outcome definitions in OHFRS research typically bundle severe endpoints such as death, monitored unit admission, airway escalation or new noninvasive ventilation, myocardial infarction, and relapse requiring admission within the follow-up window. Exact endpoint specifications vary slightly across publications, so institutions adopting the scale should align quality metrics and education materials with the definitions used in their reference sources.
Integrating OHFRS into emergency department workflow
Effective use of the OHFRS is less about memorizing point values and more about embedding a structured assessment into care. Teams can pair the score with repeated vital signs after therapy, a clear oxygen weaning plan when safe, medication reconciliation focused on diuretics and guideline-directed therapy, and explicit follow-up timing. For patients near disposition thresholds, the score can facilitate communication with cardiology, hospital medicine, and primary care by summarizing objective risk factors in a standardized way.
The scale should be interpreted dynamically. A patient who improves substantially with treatment may still retain historical and laboratory risk markers that keep the score high; conversely, a lower score does not eliminate the need to reassess if new chest pain, arrhythmia, worsening hypoxemia, or altered mental status develops. Nursing observations, urine output trends when available, and point-of-care ultrasound findings (if used locally) can complement the score without replacing it.
Limitations and responsible use
The OHFRS does not incorporate every variable that influences prognosis, including left ventricular ejection fraction, natriuretic peptide trends over time, liver congestion scores, lactate, detailed comorbidity indices, or patient-reported functional capacity beyond the brief walk test. Troponin interpretation requires assay-specific cutoffs and serial sampling strategies. Walk test performance may be limited by musculoskeletal disease, balance impairment, or language barriers, even when cardiopulmonary status has improved.
External validity may differ across health systems with varying access to follow-up, home oxygen, telehealth, and specialty clinics. Finally, the OHFRS is a risk estimation tool, not a mandate: two patients with identical scores may warrant different dispositions based on caregiver support, geographic distance to care, prior adherence, and individual preferences after informed discussion.